Taste and Smell Disturbance Resulting From Midodrine

Horger, Stephanie; Kandrac, Stacy; Longyhore, Daniel S.

doi:10.1177/0897190015627403

Cited by 5 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, for otolaryngologists who routinely use topical tetracaine, lidocaine, and phenylephrine in their offices, although tetracaine and lidocaine do cause a transient increase in olfactory threshold during the visit, these medications appear safe and without long-term effect on the olfactory system. 403,404,405 Multiple medications can have detrimental effects on olfaction.…”

Section: E Related To Medicationsmentioning

confidence: 99%

International consensus statement on allergy and rhinology: Olfaction

Patel

Holbrook

Turner

et al. 2022

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background:The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this literature and a need to consolidate and critically review the evidence. It is with that aim that we have gathered experts from around the world to produce this International Consensus on Allergy and Rhinology: Olfaction (ICAR:O). Methods: Using previously described methodology, specific topics were developed relating to olfaction. Each topic was assigned a literature review, evidence-based review, or evidence-based review with recommendations format as dictated by available evidence and scope within the ICAR:O document. Following iterative reviews of each topic, the ICAR:O document was integrated and reviewed by all authors for final consensus. Results:The ICAR:O document reviews nearly 100 separate topics within the realm of olfaction, including diagnosis, epidemiology, disease burden, diagnosis, testing, etiology, treatment, and associated pathologies. Conclusion:This critical review of the existing clinical olfaction literature provides much needed insight and clarity into the evaluation, diagnosis, and treatment of patients with olfactory dysfunction, while also clearly delineating gaps in our knowledge and evidence base that we should investigate further.

show abstract

Section: E Related To Medicationsmentioning

confidence: 99%

International consensus statement on allergy and rhinology: Olfaction

Patel

Holbrook

Turner

et al. 2022

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…Nasal and sinus diseases, upper respiratory tract infection, head trauma, smoking and neurodegenerative diseases are possible causes of smell disorders. Also, some anticonvulsant (15). Mechanisms that underlying drug-induced taste and/or smell alteration can be divided into two groups as primary, resulting from the direct effect of the drug and secondary, resulting from the indirect effect of the drug.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Sense of Smell in Onychomycosis Patients Receiving Terbinafine Treatment

Polat

Karapınar

KÜÇÜKYANGÖZ

et al. 2021

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Aim:The most common side effects of terbinafine are gastrointestinal symptoms. Loss of taste and smell side effects are presented in a small number of case reports. We aimed to measure the effect of terbinafine on the sense of smell and the degree of change in the sense of smell in this study. Material and Methods: Odor identification test (OIT), odor threshold test (OTT), and odor discrimination test (ODT) were applied to the patients treated with terbinafine and the control group. It was applied with "Sniffin Sticks" test pens. Smell test was performed on the patient group just before the start of terbinafine treatment and at the end of 3 months of treatment. Results: There was no statistical difference between the patient and control groups in terms of age (p=0.991) and gender (p=0.811). There was no statistical difference when the initial odor tests of the patient group and the control group were compared. The OIT value of the patient group was 10.15±1.43 at the beginning and 10.10±1.15 at the end of the treatment (p=0.743). The OTT values were 6.23±1.08 at the beginning and 6.21±0.85 at the end of the treatment (p=0.811). The ODT values were 9.71±1.44 at the beginning and 9.69±1.34 at the end of the treatment (p=0.767). There was no statistical difference in the results of the tests performed at the beginning and end of the treatment. Conclusion:There was no adverse effect on the sense of smell associated with the use of systemic terbinafine treatment for 3 months.

show abstract

“…In healthy volunteers, oral doses of 2.5 mg demonstrated peak plasma midodrine and desglymidodrine concentrations within 30 and 60 minutes, respectively. 8 Both midodrine and desglymidodrine are renally excreted 10 and neither crosses the blood-brain barrier. 10 The safety profi le of midodrine has been welldescribed.…”

Section: Pharmacological Profilementioning

confidence: 99%

“…8 Both midodrine and desglymidodrine are renally excreted 10 and neither crosses the blood-brain barrier. 10 The safety profi le of midodrine has been welldescribed. Reported side eff ects are most commonly the result of direct sympathomimetic activity.…”

Section: Pharmacological Profilementioning

confidence: 99%

“…[11][12][13] There have also been 2 reported cases of dysgeusia and dysosmia following initiation of midodrine at a dose of 5 mg 3 times daily for orthostatic hypotension. 10 Supine hypertension (>180/110 mmHg) is reported in 25% of patients at a dose of 10 mg 3-times daily; however, this risk is minimized when the drug is administered at least 4 hours prior to bedtime. If required, supine hypertension may be reversed with phentolamine, an alpha-1 specifi c antagonist.…”

Section: Pharmacological Profilementioning

confidence: 99%

See 1 more Smart Citation

The Role of Midodrine for Hypotension Outside of the Intensive Care Unit

Gutman

Wilson

2017

JPTCP

View full text Add to dashboard Cite

Midodrine is an oral, peripherally acting alpha-adrenergic agonist. After gaining Food and Drug Administration (FDA) approval in 1996 for orthostatic hypotension, its use has evolved to target vasoplegic conditions such as intradialytic hypotension in the end-stage renal disease population, refractory ascites in cirrhotic patients to support diuresis, and in hepatorenal syndrome. Upon oral ingestion, the drug undergoes enzymatic hydrolysis to an active metabolite, desglymidodrine. Its use has been well tolerated at 2.5 mg, 5 mg, and 10 mg oral doses. The most frequently occurring side effects relate directly to its sympathomimetic profile and include piloerection, scalp pruritis, generalized paresthesias, and urinary retention. The vasoplegic profile of sepsis would be a potential target for midodrine therapy. While its use to mediate recovery from septic shock has been suggested, there is a paucity of clinical data supporting its use. Such therapy may be uniquely appropriate in septic patients who are not candidates for intensive care unit (ICU) level of care.

show abstract

Taste and Smell Disturbance Resulting From Midodrine

Abstract: Using midodrine may result in dysgeusia and dysosmia. According to this case, both adverse effects may lessen or resolve over time with the use of the medication.

Cited by 5 publications

References 12 publications

International consensus statement on allergy and rhinology: Olfaction

International consensus statement on allergy and rhinology: Olfaction

Evaluation of Sense of Smell in Onychomycosis Patients Receiving Terbinafine Treatment

The Role of Midodrine for Hypotension Outside of the Intensive Care Unit

Contact Info

Product

Resources

About